tbuckley/cabot-search huggingface dataset:
Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience
Authors: Rouslan Kotchetkov, Esther Masih-Khan, Chia-Min Chu, Young Trieu, Saima Dean, Manjula Maganti, Christine I. Chen, Vishal Kukreti, Suzanne Trudel, Donna E. Reece
Journal: Blood (2012)
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Authors: Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL). Experimental Design: Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from Eμ-TCL1 transgenic mice are transplanted into C57BL/6 mice, and the human NSG primary CLL xenograft model. Mice received either vehicle or acalabrutinib formulated into the drinking water. Results: Utilizing biochemical assays, we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib. In the human CLL NSG xenograft model, treatment with acalabrutinib demonstrated on-target effects, including decreased phosphorylation of PLCγ2, ERK, and significant inhibition of CLL cell proliferation. Furthermore, tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice. Similarly, in the TCL1 adoptive transfer model, decreased phosphorylation of BTK, PLCγ2, and S6 was observed. Most notably, treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle. Conclusions: Treatment with acalabrutinib potently inhibits BTK in vivo, leading to on-target decreases in the activation of key signaling molecules (including BTK, PLCγ2, S6, and ERK). In two complementary mouse models of CLL, acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment. Overall, acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy in vivo on par with ibrutinib. Clin Cancer Res; 23(11); 2831–41. ©2016 AACR.
Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)
Authors: Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Uwe Platzbecker, Alan F List, Jianhua Zhong, Chengqing Wu, Konstantinos Mavrommatis, C.L. Beach, Albert Hoenekopp, Kyle J. MacBeth
Journal: Blood (2016)
Decreased Expression In NF-κB Essential Modulator Due to a Novel Splice-Site Mutation Causes Ectodermal Dysplasia with Immunodeficiency
Authors: Shuhei Karakawa, Satoshi Okada, Miyuki Tsumura, Yoko Mizoguchi, Norioki Ohno, Shin'ichiro Yasunaga, Motoaki Ohtsubo, Tomoki Kawai, Ryuta Nishikomori, Yoshihiro Takihara, Masao Kobayashi
Journal: Blood (2010)
Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.
Authors: Ifat Geron, Charlene Barroga, Jason Gotlib, Edward Kavalerchik, Annelie Abrahamsson, Daniel Goff, Nicholas Cacalano, John Hood, Richard Soll, Glenn Noronha, Ayalew Tefferi, Irving L. Weissman, Kenneth Kaushansky, Catriona Jamieson
Journal: Blood (2006)
Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.
Authors: Jorge E. Cortes, H. Jean Khoury, Jeff H Lipton, Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Eric Leip, Virginia Kelly, Nadine Besson, Kathleen Turnbull, Hagop M. Kantarjian
Journal: Blood (2012)
Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients:
Authors: Jaap Jan Zwaginga, Ronnie van der Holt, Bart J. Biemond, Peter A.W. te Boekhorst, Mark Levin, Art Vreughdenhil, P.C. Huijgens, Anneke Brand, Rene van der Griend, Marleen Luten, Hans Pruijt, Okke de Weerdt, Elisabeth van Pampus, Sonja Zweegman, Rene Hollestein, Harry R. Koene
Journal: Blood (2010)
Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium
Authors: Ju Dong Yang, Essa A Mohamed, Ashraf O Abdel Aziz, Hend I Shousha, Mohamed B Hashem, Mohamed M Nabeel, Ahmed H Abdelmaksoud, Tamer M Elbaz, Mary Y Afihene, Babatunde M Duduyemi, Joshua P Ayawin, Adam Gyedu, Marie-Jeanne Lohouès-Kouacou, Antonin W Ndjitoyap Ndam, Ehab F Moustafa, Sahar M Hassany, Abdelmajeed M Moussa, Rose A Ugiagbe, Casimir E Omuemu, Richard Anthony, Dennis Palmer, Albert F Nyanga, Abraham O Malu, Solomon Obekpa, Abdelmounem E Abdo, Awatif I Siddig, Hatim M Y Mudawi, Uchenna Okonkwo, Mbang Kooffreh-Ada, Yaw A Awuku, Yvonne A Nartey, Elizabeth T Abbew, Nana A Awuku, Jesse A Otegbayo, Kolawole O Akande, Hailemichael M Desalegn, Abidemi E Omonisi, Akande O Ajayi, Edith N Okeke, Mary J Duguru, Pantong M Davwar, Michael C Okorie, Shettima Mustapha, Jose D Debes, Ponsiano Ocama, Olufunmilayo A Lesi, Emuobor Odeghe, Ruth Bello, Charles Onyekwere, Francis Ekere, Rufina Igetei, Mitchell A Mah'moud, Benyam Addissie, Hawa M Ali, Gregory J Gores, Mark D Topazian, Lewis R Roberts
Journal: The Lancet. Gastroenterology & hepatology (2016)
Infliximab Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease After Reduced-Intensity Cord Blood Transplantation in Adults
Authors: Kazuya Ishiwata, Aya Nishida, Hikari Ota, Taichi Ikebe, Masanori Tsuji, Hisashi Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu, Shuichi Taniguchi
Journal: Blood (2011)
Précis of <i>Talking to Our Selves: Reflection, Ignorance, and Agency</i>
Authors: John M. Doris
Journal: Behavioral and Brain Sciences (2016)

Does it make sense for people to hold one another responsible for what they do, as happens in countless social interactions every day? One of the most unsettling lessons from recent psychological research is that people are routinely mistaken about the origins of their behavior. Yet philosophical orthodoxy holds that the exercise of morally responsible agency typically requires accurate self-awareness. If the orthodoxy is right, and the psychology is to be believed, people characteristically fail to meet the standards of morally responsible agency, and we are faced with the possibility of skepticism about agency. Unlike many philosophers, I accept the unsettling lesson from psychology. I insist, however, that we are not driven to skepticism. Instead, we should reject the requirement of accurate self-awareness for morally responsible agency. In Talking to Our Selves I develop a dialogic theory, where the exercise of morally responsible agency emerges through a collaborative conversational process by which human beings, although afflicted with a remarkable degree of self-ignorance, are able to realize their values in their lives.
Rituximab-CHOP and Rituximab-ESHAP/MINE in B Follicular and Diffuse NHL as Front Line Therapy in Newly Diagnosed and Relapsed Patients.
Authors: Jorge I. Herrera-Cepeda, Angel Urdaneta, Dalai Montero-Escobar, Maira Urdaneta-Herrera, Roger Davis-Hazim, Raul Ocando-M, Maria A. Lopez, Glenda R. Marquez-Herrera
Journal: Blood (2006)
Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.
Authors: Anas Younes, Michelle Fanale, Peter McLaughlin, Amanda R Copeland, Silvana de Castro Faria, Jeanette Wood, Kantharaj Ethirajulu, Huan J. Zhu
Journal: Blood (2009)
AML FAB Subtypes Shows Different Proportion of Leukemia Initiating Cell Which Has Lower Single Cell Dividing Property.
Authors: Hye Ran Kim, Myung-Geun Shin, Yester Kim, Hyeoung Joon Kim, Duck Cho, Seung-Jung Kee, Soo-Hyun Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang
Journal: Blood (2009)
A Short Pulse of Prostaglandin E2 (PGE2) Induces Long Term Chromatin Changes in Hematopoietic Stem Cells Leading to Increased Self-Renewal and Engraftment
Authors: Eva M Fast, Ellen M Durand, Audrey Sporrij, Leslie Ojeaburu, Rebecca Maher, Vera Binder, Song Yang, Yi Zhou, Leonard I. Zon
Journal: Blood (2015)
Rb Regulates Erythroid Differentiation through Bcl-XL-Dependent Anti-Apoptotic Effect.
Authors: Sahoko Matsuoka, Atsushi Hirao, Fumio Arai, Keisuke Ito, Keiyo Takubo, Kana Nomiyama, Isao Hamaguchi, Yasuo Ikeda, Toshio Suda
Journal: Blood (2004)
NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
Authors: P.M. Forde, K.N. Smith, J.E. Chaft, M. Hellmann, T. Merghoub, J.D. Wolchok, S.C. Yang, R.J. Battafarano, E. Gabrielson, C.S. Georgiades, F. Verde, G.L. Rosner, J. Naidoo, T.R. Cottrell, J.M. Taube, V. Anagnostou, V.E. Velculescu, S.L. Topalian, D.M. Pardoll, J.R. Brahmer
Journal: Annals of Oncology (2016)
Differential Signaling of G Protein-Coupled Chemotactic Receptors (CXCR4, cysLT1 and S1P1) Expressed in Hematopoietic Progenitor Cells.
Authors: Xingkui Xue, Andreas Boehmler, Lothar Kanz, Gabriele Seitz, Robert Mohle
Journal: Blood (2006)
Etodolac Induces Apoptosis and Inhibits Cell Adhesion to Bone Marrow Stromal Cells in Human Myeloma Cells.
Authors: Satoki Nakamura, Miki Kobayashi, Kiyoshi Shibata, Naohi Sahara, Kazuyuki Shigeno, Kaori Shinjo, Kensuke Naito, Kazunori Ohnishi
Journal: Blood (2004)
How Are Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS) Treated? Impact on Clinical Evolution and Overall Survival: A Report from the Erasme Study
Authors: Julia Montoro, Helena Pomares, Itziar Oiartzabal, Teresa Bernal, Edgardo Barranco, Rosa Coll, Rafael Romero, Marisa Calabuig, Eduardo Salido, Marta Castellanos, Angeles Medina, Gemma Azaceta, Mireya Navarro, Silvia López, David Valcárcel
Journal: Blood (2015)
CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).
Authors: Francis Giles, Susan O’Brien, David Rizzieri, Judith Karp, Maureen Cooper, Ghulam Mufti, Bonny Johnson, Verena Karsten, Norbert Vey
Journal: Blood (2005)
The Relationship Between Some Cytokines and Graft Versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Thalassemia Major Patients
Authors: Xuedong Wu, Libai Chen, Yanjun Xu, Jianyun Wen, Yongsheng Ruan, Yuelin He, Chunfu Li
Journal: Blood (2015)
Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB).
Authors: Guido Marcucci, C.D. Baldus, A.S. Ruppert, M.D. Radmacher, K. Mrózek, S.P. Whitman, J.E. Kolitz, C.G. Edwards, J.W. Vardiman, B.L. Powell, M.R. Baer, J.O. Moore, D. Perrotti, M.A. Caligiuri, A.J. Carroll, R.A. Larson, A. de la Chapelle, C.D. Bloomfield
Journal: Blood (2005)
Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease
Authors: Kristen Detweiler Short, S. Vincent Rajkumar, Francis Buadi, Dirk Larson, Suzanne R. Hayman, Angela Dispenzieri, Morie Abraham A Gertz, Shaji Kumar, Joseph R. Mikhael, Vivek Roy, Robert Kyle, Martha Lacy
Journal: Blood (2010)
Abstract #2077: Antagonistic antibodies to c-fms block c-fms-mediated activities, reduce tumor-associated macrophages and decrease tumor growth in preclinical models
Authors: Lynn Bonham, Daniel Branstetter, Chris Russell, Kristin Kucera, Jayne Schaubhut, David Peckham, Nathan Hedin, Alexey Ball, Jeffrey Smith, Christopher Mehlin, Ning Weng, Ilan Kirsch
Journal: Cancer Research (2009)

Tumor associated macrophages (TAMs) produce numerous factors that may directly and indirectly support tumor growth and progression. In support of this view, a variety of tumor types with high TAM content, elevated c-fms (CSF-1 receptor) and CSF-1 levels have been associated with poor prognosis in cancer patients. Given that the CSF-1/c-fms signaling pathway drives the proliferation and function of macrophages, we developed antagonistic antibodies to c-fms and assessed the effects of these antibodies on monocytic cells in vitro and TAMs and tumor growth in vivo. In this study, AMG 820, a fully human monoclonal antibody antagonist to c-fms potently inhibited CSF-1 binding to its receptor and CSF-1-driven proliferation of the human myelomonocytic cell line AML-5 as well as primary human bone-marrow derived macrophages (IC-50s range 5-30 pM). Similarly, M279, an antibody to mouse c-fms, inhibited CSF-1-driven mouse myelomonocytic cell line growth. Interestingly, both AMG 820 and M279 significantly inhibited the effects, with similar potencies, of both CSF-1 and IL-34, the recently discovered second ligand for c-fms. M279 and AMG 820 also blocked c-fms activity in vivo in mice and Cynomolgus monkeys, respectively, as shown by significant increases in serum CSF-1 (blockade of c-fms-mediated CSF-1 degradation) as well as decreases in serum Trap 5b through the inhibition of the CSF-1/c-fms axis in osteoclasts. In several preclinical tumor models in mice, these systemic effects were accompanied by consistent reduction of TAMs by 70-80% based upon laser scanning cytofluorometric quantitation of F4/80-positive cells. TAM reduction was associated with a decrease in tumor volume in some models as well as an increase in necrosis and decreased viable tumor by histopathological analysis. Taken together, these data indicate that the treatment with an antagonistic antibody to c-fms reduce TAMs and TAM-mediated support of tumor growth, thus providing a novel approach to cancer therapy.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2077.
Comparison of the PI3K-δ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro
Authors: Daphne R. Friedman, Mark C. Lanasa, Danielle M. Brander, Sallie D. Allgood, Evan D. Davis, Hari Miskin, Srikant Viswanadha, Swaroop Vakkalanka, J. Brice Weinberg
Journal: Blood (2012)
Bis(1H-indol-2yl)methanones Are Effective Inhibitors of Mutated FLT3 Tyrosine Kinase, Overcome Resistance to PKC412A In Vitro and Show Synergy with Chemotherapy.
Authors: Florian Heidel, Fian K. Mirea, Frank Breitenbucher, Stefan Dove, Christoph Huber, Frank D. Bohmer, Thomas Fischer
Journal: Blood (2006)
Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).
Authors: Yazan Alsayed, Ujjal Singha, Lanie Francis, Alissa Huston, Ganwei Lu, Judy Anderson, Suzanne Lentzsch, G. David Roodman, Irene Ghobrial
Journal: Blood (2005)
TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis
Authors: Austin G Kulasekararaj, Alexander E Smith, Syed A Mian, Pramila Krishnamurthy, Azim M Mohamedali, Nicholas C Lea, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, Sabine Pomplun, ZiYi Lim, Judith C. W. Marsh, Ghulam J. Mufti
Journal: Blood (2011)
Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index
Authors: Kiran Naqvi, Maria E Suarez-Almazor, Sagar Sardesai, Jeong Oh, Carlos Vigil, Sherry Pierce, Xiudong Lei, Jianqin Shan, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2010)
Progressive Telomere Shortening During the Natural History of Chronic Lymphocytic Leukemia
Authors: E Genuardi, D Rossi, E Bernocco, Cl Bodoni, D Drandi, M Coscia, M Ruggeri, M Fangazio, P Ghione, Gattei, M Boccadoro, P Omede, M Massaia, G Gaidano, M Ladetto
Journal: Annals of Oncology (2011)
Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis
Authors: Deepak R Jadon, Raj Sengupta, Alison Nightingale, Mark Lindsay, Eleanor Korendowych, Graham Robinson, Amelia Jobling, Gavin Shaddick, Jing Bi, Robert Winchester, Jon T Giles, Neil J McHugh
Journal: Annals of the Rheumatic Diseases (2016)

Objectives To compare the prevalence, clinical and radiographic characteristics of psoriatic spondyloarthritis (PsSpA) in psoriatic arthritis (PsA), with ankylosing spondylitis (AS). Methods A prospective single-centre cross-sectional observational study recruited consecutive PsA and AS cases. Participants completed outcome measures, and underwent clinical examination, axial radiographic scoring and HLA- sequencing. Multivariable analyses are presented. Results The 402 enrolled cases (201 PsA, 201 AS; fulfilling classification criteria for respective conditions) were reclassified based upon radiographic axial disease and psoriasis, as: 118 PsSpA, 127 peripheral-only PsA (pPsA), and 157 AS without psoriasis (AS) cases. A significant proportion of patients with radiographic axial disease had PsSpA (118/275; 42.91%), and often had symptomatically silent axial disease (30/118; 25.42%). Modified New York criteria for AS were fulfilled by 48/201 (23.88%) PsA cases, and Classification of Psoriatic Arthritis criteria by 49/201 (24.38%) AS cases. pPsA compared with PsSpA cases had a lower frequency of HLA-B*27 (OR 0.12; 95% CI 0.05 to 0.25). Disease activity, metrology and disability were comparable in PsSpA and AS. A significant proportion of PsSpA cases had spondylitis without sacroiliitis (39/118; 33.05%); they less frequently carried HLA-B*27 (OR 0.11; 95% CI 0.04 to 0.33). Sacroiliac joint complete ankylosis (adjusted OR, OR adj 2.96; 95% CI 1.42 to 6.15) and bridging syndesmophytes (OR adj 2.78; 95% CI 1.49 to 5.18) were more likely in AS than PsSpA. Radiographic axial disease was more severe in AS than PsSpA (Psoriatic Arthritis Spondylitis Radiology Index Score: adjusted incidence risk ratio 1.13; 95% CI 1.09 to 1.19). Conclusions In a combined cohort of patients with either PsA or AS from a single centre, 24% fulfilled classification criteria for both conditions. The pattern of axial disease was influenced significantly by the presence of skin psoriasis and HLA-B*27 .
Retrospective Study of the Utility of Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 In Patients with Follicular Lymphoma Uniformly Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, and Prednisone
Authors: Ayumi Numata, Katsumichi Fujimaki, Naoto Tomita, Masatsugu Tanaka, Chizuko Hashimoto, Rika Oshima, Kenji Matsumoto, Shiro Matsuura, Wataru Yamamoto, Shigeki Motomura, Yoshiaki Ishigatsubo
Journal: Blood (2010)
Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).
Authors: Deborah A. Thomas, Hagop M. Kantarjian, Leonard Heffner, Wendy Stock, Guillermo Garcia-Manero, Stefan Faderl, Alessandra Ferrajoli, Francis Giles, William Wierda, Farhad Ravandi-Kashani, Gavin Choy, Gregory I. Berk, Susan O’Brien
Journal: Blood (2006)
DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG
Authors: Verena I. Gaidzik, Richard F. Schlenk, Peter Paschka, Anja Stölzle, Andrea Corbacioglu, David Nachbaur, Thomas Kindler, Alexander C. Burchardt, Helmut R. Salih, Hans-Günther Mergenthaler, Hans J. Salwender, Daniela Späth, Lars Bullinger, Juergen Krauter, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2011)
Factors That Contribute to Long-Term Survival In Patients with Leukemia Not In Remission at Allogeneic Hematopoietic Cell Transplantation
Authors: Hideo Koh, Hirohisa Nakamae, Takahiko Nakane, Masahiro Manabe, Yoshiki Hayashi, Mitsutaka Nishimoto, Kaori Umemoto, Mika Nakamae, Asao Hirose, Eri Inoue, Atsushi Inoue, Masahiro Yoshida, Masato Bingo, Hiroshi Okamura, Ran Aimoto, Mizuki Aimoto, Yoshiki Terada, Ki-Ryang Koh, Takahisa Yamane, Masayuki Hino
Journal: Blood (2010)
Nucleotide Receptor P2Y14 Modulates Hematopoietic Stem Cell Response to Tissue Injury Altering Stem Cell Preservation and Tissue Recovery.
Authors: Yoriko Saito, Eyal Attar, Samyukta Jana, David Dombkowski, Viktor Janzen, Byeong-Chel Lee, Alastair D. Morrison, Alejandro Abuin, Sue Pickering, George P. Livi, Gregor B. Adams, David T. Scadden
Journal: Blood (2006)
Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory
Authors: Mathieu Molimard, Stephane Bouchet, Gabriel Etienne, Laurence Legros, Delphine Rea, Francoise Huguet, Karine Titier, Nicholas Moore, Josy Reiffers, Coralie Belanger, Francois-Xavier Mahon
Journal: Blood (2008)
Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS.
Authors: Detlef Haase, Elihu H. Estey, Christian Steidl, Ulrich Germing, Guillermo Garcia-Manero, Hagop M. Kantarjian, Julie Schanz
Journal: Blood (2007)
Treatment of acute colonic diverticular bleeding in high risk patients, using an over-the-scope clip: a case series
Authors: Edris Wedi, Daniel von Renteln, Carlo Jung, Irina Tchoumak, Victor Roth, Susana Gonzales, Joel Leroy, Juergen Hochberger
Journal: Endoscopy (2016)

The prevalence of diverticulosis has increased in industrialized countries in recent years and the condition is reported in up to 60 % of patients older than 70 years [1] [2]. Diverticular disease is one of the most common causes of lower gastrointestinal bleeding and accounts for 30 % – 40 % of all such bleeds [3] [4]. Many diverticular bleeding episodes resolve spontaneously. However, according to the literature about 50 % of patients require blood transfusion and 18 % – 53 % need emergency surgery [2]. Patients undergoing anticoagulation treatment or presenting with severe hemorrhage are at high risk of both morbidity and mortality.
Up-Regulation of Heme Oxygenase-1 Is Induced by the Leukemia Stroma-Cell Interaction and Rescues Acute Myeloid Leukaemia (AML) Cells From Cytarabin Induced Cell Death
Authors: Cornelia A. Brendel, Xiaonan Wang, Katharina Henkenius, Mihaela Pali, Torsten Haferlach, Thorsten Stiewe, Andreas Neubauer
Journal: Blood (2012)